ganaplacide (KAF156) / Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ganaplacide (KAF156) / Novartis
NCT01753323: Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

Completed
2
43
RoW
KAF156
Novartis Pharmaceuticals
Malaria
08/14
08/14
NCT03167242 / 2020-003284-25: Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Completed
2
524
RoW
KAF156, KAF, Coartem, Lumefantrine Solid Dispersion Formulation, LUM-SDF and LUM
Novartis Pharmaceuticals, Medicines for Malaria Venture
Acute Uncomplicated Plasmodium Falciparum Malaria
06/21
06/21
NCT04546633: Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria

Recruiting
2
295
RoW
KAF156, LUM-SDF, Lumefantrine Solid Dispersion Formulation, Coartem
Novartis Pharmaceuticals, European and Developing Countries Clinical Trials Partnership (EDCTP)
Uncomplicated Plasmodium Falciparum Malaria
07/24
08/24

Download Options